Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05038982 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05038982: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT05038982 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05038982, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary objective is to assess the efficacy, safety, and tolerability of Abrocitinib for the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in patients experiencing moderate to severe pruritus.
Interventions
- DRUG Abrocitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2022-07-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05038982
The ClinicalTrials.gov registry entry for NCT05038982 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abrocitinib is the first listed.
NCT05038982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05038982 about?
NCT05038982 is a clinical study titled "Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin". The primary objective is to assess the efficacy, safety, and tolerability of Abrocitinib for the treatment of Prurigo Nodularis (PN) or Chronic Pruritus of Unknown Origin (CPUO) in patients experiencing moderate to severe pruritus.
What is the current status of trial NCT05038982?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-09-09. Estimated completion is 2022-07-11.
What interventions are being tested in trial NCT05038982?
The interventions under investigation include: Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT05038982?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.